Every active, company-sponsored Phase 3 in the cohort, by the primary completion date on its registry record. Registry dates are the sponsor's estimate and move.
| Primary completion | Company | Indication | Market cap | Runway (qtrs) | |
|---|---|---|---|---|---|
| 2026-09-01 | RGNX | Regenxbio Inc | Mucopolysaccharidosis Type II (MPS II) | $638M | 2.5 |
| 2026-09-01 | ARDX | Ardelyx Inc | Irritable Bowel Syndrome With Constipati | $984M | 20.5 |
| 2026-09-01 | VNDA request | Vanda Pharmaceuticals Inc | Social Anxiety Disorder (SAD) | $320M | 9.5 |
| 2026-09-01 | IRON request | Disc Medicine Inc | Erythropoietic Protoporphyria (EPP) | $3,073M | 10.9 |
| 2026-09-01 | INCY request | Incyte Corp | Chronic Graft-versus-host-disease | $25,210M | — |
| 2026-09-01 | ALKS request | Alkermes Plc | Narcolepsy Type 1 | $7,954M | — |
| 2026-09-17 | VRTX request | Vertex Pharmaceuticals Inc | Beta-Thalassemia | $137,297M | — |
| 2026-09-28 | OCGN | Ocugen Inc | Stargardt Disease | $448M | 6.1 |
| 2026-10-01 | BHVN | Biohaven Ltd | Focal Epilepsy | $2,328M | 1.7 |
| 2026-10-01 | CLDX | Celldex Therapeutics Inc | Chronic Inducible Urticaria | $3,072M | 9.5 |
| 2026-10-01 | MIRM request | Mirum Pharmaceuticals Inc | Chronic Hepatitis D Infection | $5,943M | 2.1 |
| 2026-10-01 | ABBV request | Abbvie Inc | AMD | $451,463M | — |
| 2026-10-07 | REGN request | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer | $81,766M | — |
| 2026-10-31 | OLMA | Olema Pharmaceuticals Inc | Breast Cancer | $899M | 8.4 |
| 2026-10-31 | ANNX | Annexon Inc | Geographic Atrophy | $942M | 3.9 |
| 2026-10-31 | SRPT | Sarepta Therapeutics Inc | Muscular Dystrophy, Duchenne | $2,203M | — |
| 2026-10-31 | TGTX | Tg Therapeutics Inc | Relapsing Multiple Sclerosis | $8,256M | — |
| 2026-11-01 | CGON request | Cg Oncology Inc | Non Muscle Invasive Bladder Cancer | $6,590M | 16.3 |
| 2026-11-01 | SRRK request | Scholar Rock Holding Corp | Spinal Muscular Atrophy | $7,039M | 4.6 |
| 2026-12-01 | CMPX | Compass Therapeutics Inc | Biliary Tract Cancer | $432M | 8.5 |
| 2026-12-01 | VIR | Vir Biotechnology Inc | Viral Hepatitis | $1,833M | 6.0 |
| 2026-12-01 | KRYS request | Krystal Biotech Inc | Dystrophic Epidermolysis Bullosa | $10,403M | — |
| 2026-12-01 | IONS request | Ionis Pharmaceuticals Inc | Hereditary Angioedema (HAE) | $10,146M | 13.8 |
| 2026-12-01 | MDGL request | Madrigal Pharmaceuticals Inc | NASH | $12,332M | 10.8 |
| 2026-12-01 | UTHR request | United Therapeutics Corp | Idiopathic Pulmonary Fibrosis | $22,108M | — |
| 2026-12-15 | EXEL request | Exelixis Inc | Metastatic Prostate Cancer | $13,492M | — |
| 2026-12-31 | INSM request | Insmed Inc | Pulmonary Hypertension | $25,887M | 2.6 |
| 2027-01-01 | PCVX request | Vaxcyte Inc | Pneumococcal Vaccines | $8,904M | 5.3 |
| 2027-01-01 | BBIO request | Bridgebio Pharma Inc | Hypochondroplasia | $14,975M | 5.6 |
| 2027-01-15 | IDYA | Ideaya Biosciences Inc | Uveal Melanoma | $3,870M | 15.7 |
| 2027-02-01 | KOD | Kodiak Sciences Inc | Macular Edema Secondary to Inflammation | $2,371M | 2.1 |
| 2027-03-01 | STOK | Stoke Therapeutics Inc | Dravet Syndrome | $2,040M | 6.2 |
| 2027-03-13 | RYTM request | Rhythm Pharmaceuticals Inc | Hypothalamic Obesity | $7,379M | 6.7 |
| 2027-05-01 | VOR | Vor Biopharma Inc | Primary Sjogren's Disease | $1,340M | 2.0 |
| 2027-06-01 | SVRA request | Savara Inc | Autoimmune Pulmonary Alveolar Proteinosi | $1,081M | 4.9 |
| 2027-06-01 | DNLI request | Denali Therapeutics Inc | Mucopolysaccharidosis II | $3,836M | 5.3 |
| 2027-06-01 | GILD request | Gilead Sciences Inc | Triple Negative Breast Cancer | $180,637M | 10.8 |
| 2027-07-01 | NTLA | Intellia Therapeutics Inc | Neuromuscular Disease | $1,803M | 4.0 |
| 2027-07-01 | VKTX | Viking Therapeutics Inc | Weight Loss | $3,752M | 4.3 |
| 2027-07-01 | NBIX request | Neurocrine Biosciences Inc | Congenital Adrenal Hyperplasia | $15,660M | — |
| 2027-08-01 | TVTX request | Travere Therapeutics Inc | Homocystinuria | $6,190M | 56.8 |
| 2027-09-01 | CYTK request | Cytokinetics Inc | Pediatric | $10,022M | 7.3 |
| 2027-11-01 | CRVS | Corvus Pharmaceuticals Inc | Peripheral T-Cell Lymphoma, Not Otherwis | $1,191M | 15.7 |
| 2027-12-01 | IMVT request | Immunovant Inc | Generalized Myasthenia Gravis | $8,510M | — |
| 2027-12-01 | RVMD request | Revolution Medicines Inc | NSCLC | $44,556M | 10.3 |
| 2027-12-27 | ALNY request | Alnylam Pharmaceuticals Inc | Transthyretin Amyloidosis With Cardiomyo | $31,726M | — |
| 2027-12-31 | PTCT request | Ptc Therapeutics Inc | Phenylketonuria | $5,850M | — |
| 2028-01-01 | ACAD request | Acadia Pharmaceuticals Inc | Alzheimer's Disease Psychosis | $5,016M | — |
| 2028-03-01 | ORIC request | Oric Pharmaceuticals Inc | Metastatic Castration Resistant Prostate | $1,372M | 3.2 |
| 2028-03-01 | IOVA | Iovance Biotherapeutics Inc | Metastatic Melanoma | $3,628M | 3.5 |
| 2028-03-01 | HALO request | Halozyme Therapeutics Inc | Hypogonadism, Male | $11,957M | — |
| 2028-04-01 | RCUS request | Arcus Biosciences Inc | Metastatic Pancreatic Ductal Adenocarcin | $3,674M | 7.4 |
| 2028-04-01 | BCAX request | Bicara Therapeutics Inc | Metastatic Head and Neck Squamous Cell C | $1,550M | 8.6 |
| 2028-04-01 | SMMT | Summit Therapeutics Inc | Metastatic Colorectal Cancer (CRC) | $10,953M | — |
| 2028-04-01 | ERAS request | Erasca Inc | Advanced or Metastatic NRAS-mutant Melan | $6,306M | 1.3 |
| 2028-04-30 | RLAY request | Relay Therapeutics Inc | PIK3CA Mutation | $4,113M | 1.5 |
| 2028-06-30 | GERN | Geron Corp | Myelodysplastic Syndromes | $970M | 40.4 |
| 2028-07-01 | CABA | Cabaletta Bio Inc | Systemic Sclerosis | $529M | 4.8 |
| 2028-07-01 | DYN request | Dyne Therapeutics Inc | Duchenne Muscular Dystrophy (DMD) | $4,682M | 6.7 |
| 2028-09-01 | IBRX | Immunitybio Inc | Bladder Cancer | $8,532M | 5.5 |
| 2028-10-15 | VSTM | Verastem Inc | Low Grade Serous Ovarian Cancer | $654M | 3.8 |
| 2028-12-01 | DNTH request | Dianthus Therapeutics Inc | Myasthenia Gravis, Generalized | $5,920M | 19.4 |
| 2029-01-01 | SLDB request | Solid Biosciences Inc | Duchenne Muscular Dystrophy | $1,048M | 7.4 |
| 2029-02-01 | AVBP request | Arrivent Biopharma Inc | Non-Small-Cell Lung Cancer | $1,488M | 8.7 |
| 2029-03-01 | AGIO request | Agios Pharmaceuticals Inc | Pediatric Pyruvate Kinase Deficiency | $1,989M | 5.3 |
| 2029-03-31 | CELC request | Celcuity Inc | Breast Cancer | $4,328M | 14.8 |
| 2029-05-01 | INBX request | Inhibrx Biosciences Inc | Head and Neck Squamous Cell Carcinoma (H | $1,816M | 4.3 |
| 2029-06-01 | SNDX request | Syndax Pharmaceuticals Inc | Acute Myeloid Leukemias | $1,745M | 10.9 |
| 2029-06-01 | BMRN request | Biomarin Pharmaceutical Inc | Hemophilia A | $12,517M | — |
| 2030-01-01 | REPL | Replimune Group Inc | Advanced Melanoma | $1,460M | 2.5 |
| 2030-02-01 | VCEL request | Vericel Corp | Chondral Defect | $2,097M | 104.7 |
| 2030-06-01 | ZBIO request | Zenas Biopharma Inc | Multiple Sclerosis (MS) Primary Progress | $2,038M | 8.8 |
| 2031-06-01 | TSHA request | Taysha Gene Therapies Inc | Rett Syndrome | $1,880M | 12.0 |
| 2031-08-01 | BCRX | Biocryst Pharmaceuticals Inc | Hereditary Angioedema | $2,509M | 2.6 |
| 2031-10-22 | CADL | Candel Therapeutics Inc | Non-squamous, Non-Small Cell Lung Cancer | $1,000M | 12.0 |
| 2031-11-01 | KURA | Kura Oncology Inc | Acute Myeloid Leukemia (AML) | $1,126M | 6.8 |